|
Established in late 2004 in Toronto, Ontario, Sopherion Canada, Inc. commercializes oncology and oncology-related products acquired and developed by Sopherion Therapeutics. Sopherion Canada is committed to positively affecting the quality of life and health of Canadians.
Management:
Salvatore Forenza, Ph.D.
President
Myocet®:
Myocet received Canadian regulatory approval December 21, 2001 and is indicated for the first-line treatment of metastatic breast cancer in combination with cyclophosphamide.
Please see full prescribing information: English | French
All product information provided is intended for Canadian healthcare professionals only. If you are not a healthcare professional and would like more information about any of these products, please contact your doctor. Myocet may not be available in countries outside Canada or Europe.
Product (generic name): |
Myocet® |
Indication: |
First-line treatment of metastatic breast cancer in combination with cyclophosphamide.
|
Therapeutic Focus: |
Metastatic Breast Cancer |
Product Description: |
A liposome-encapsulated doxorubicin-citrate complex developed to reduce the cardiac toxicity associated with conventional doxorubicin while delivering comparable anti-tumor efficacy. |
|
